Animal Cancer Foundation proudly announces the next milestone in the Canine Cancer Genome Project (CCGP): Phase II-Omics. This pioneering effort focuses on genomic and proteomic profiling of Canine Osteosarcoma, B-cell Lymphoma, and Soft Tissue Sarcoma. By addressing critical gaps in research, this initiative aims to uncover groundbreaking insights for both veterinary and human cancer treatments.
Mission Statement
The Canine Cancer Genome Project (CCGP) aims to advance cancer research for both pets and humans through comprehensive genomic and proteomic studies. This multi-institutional initiative, led by TGen, Ethos Discovery, Tufts University, and CHOP, focuses on identifying key cancer mutations across soft tissue sarcoma, B-cell lymphoma, and osteosarcoma in dogs. By creating a shared data portal and developing innovative bioinformatics tools, CCGP bridges canine and human cancer research, hoping to unveil targeted treatments and lifesaving insights. Public support helps propel this groundbreaking work, ultimately benefitting both pets and people in the fight against cancer.
Representing New Hope for People and Pets With Cancer
CANINE CANCER GENOME PROJECT (CCGP) FORGES AHEAD
Focuses Genomic and Proteomic Lenses on Three Difficult-to-Treat Canine Cancers
The Canine Cancer Genome Project (CCGP) is a multi-institutional initiative led by TGen, Ethos Discovery and Tufts University to advance cancer research for pets and humans through comprehensive genomic and proteomic studies. Researchers have focused on identifying key cancer mutations across three difficult-to-treat canine cancers: soft tissue sarcoma, B-Cell lymphoma, and osteosarcoma. Sponsored initially by Blue Buffalo Foundation and Animal Cancer Foundation, CCGP researchers are addressing critical gaps in scientific knowledge.
The clinical trial team is pleased to share with the general public a preview of a significant finding in the diagnosis and treatment of soft tissue sarcoma, the identification of a “molecular footprint” in some cases of the disease that was previously unknown. This new discovery will allow veterinarians to test tumors for this footprint and to target the most effective treatment possible.
As the researchers forge ahead, they anticipate discovery of more of these hidden footprints that may be the first steps in development of targeted treatments. The on-going research which is set to conclude in 2026 is poised to bring new knowledge straight to the clinic for the treatment of these diseases.
We will save the lives of more pets and more people with your help and support!
Thank you.
